{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:15:06Z","timestamp":1788538506048,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013395","name":"Sistema Nacional de Investigadores","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Secretar\u00eda de Ciencia, Humanidades, Tecnolog\u00eda e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Graphics and Modelling"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jmgm.2026.109502","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:15:47Z","timestamp":1782573347000},"page":"109502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond the catalytic site: Voxilaprevir and Pasireotide as repurposed therapeutics for conformational inhibition of ADAR1"],"prefix":"10.1016","volume":"148","author":[{"given":"Erick","family":"Bahena-Culhuac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo Gamaliel","family":"Avila-Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0683-073X","authenticated-orcid":false,"given":"Rodolfo Daniel","family":"\u00c1vila-Avil\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmgm.2026.109502_bib1","article-title":"ADAR1-Mediated RNA editing and its role in cancer","volume":"10","author":"Liu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jmgm.2026.109502_bib2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s12032-025-02979-9","article-title":"ADAR1-mediated RNA editing in breast cancer: molecular mechanisms and therapeutic implications","volume":"42","author":"Chen","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.jmgm.2026.109502_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/genes10010012","article-title":"ADAR1 editing and its role in cancer","volume":"10","author":"Xu","year":"2018","journal-title":"Genes"},{"key":"10.1016\/j.jmgm.2026.109502_bib4","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s43018-025-00907-4","article-title":"Targeting ADAR1 with a small molecule for the treatment of prostate cancer","volume":"6","author":"Wang","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.jmgm.2026.109502_bib5","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.190244","article-title":"ADAR1 expression is associated with cervical cancer progression and negatively regulates NK cell activity","volume":"10","author":"Tassinari","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.jmgm.2026.109502_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13000-017-0600-0","article-title":"ADAR1 overexpression is associated with cervical cancer progression and angiogenesis","volume":"12","author":"Chen","year":"2017","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.jmgm.2026.109502_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41388-020-01515-5","article-title":"Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer","volume":"40","author":"Kung","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.jmgm.2026.109502_bib8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-025-02312-y","article-title":"ADAR1-high tumor-associated macrophages induce drug resistance and are therapeutic targets in colorectal cancer","volume":"24","author":"Umeda","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jmgm.2026.109502_bib9","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1038\/s41388-020-1248-x","article-title":"ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity","volume":"39","author":"Ram\u00edrez-Moya","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.jmgm.2026.109502_bib10","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1038\/s41467-023-38581-8","article-title":"ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer","volume":"14","author":"Wong","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jmgm.2026.109502_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2020.118716","article-title":"ADAR1 transcriptome editing promotes breast cancer progression through the regulation of cell cycle and DNA damage response","volume":"1867","author":"Sagredo","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.jmgm.2026.109502_bib12","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-022-04753-7","article-title":"ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis","volume":"606","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jmgm.2026.109502_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.114615","article-title":"Identification of ADAR1i-124: the first effective A-to-I RNA editing inhibitor with promising cancer therapeutic potential","volume":"29","author":"Minakuchi","year":"2026","journal-title":"iScience"},{"key":"10.1016\/j.jmgm.2026.109502_bib14","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.1158\/1538-7445.AM2024-4484","article-title":"Abstract 4484: discovery of a potential first-in-class Za targeted small molecule inhibitor of ADAR1 p150 which demonstrates strong anti-tumor efficacy","volume":"84","author":"Goswami","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmgm.2026.109502_bib15","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.molcel.2025.02.017","article-title":"Biochemical profiling and structural basis of ADAR1-mediated RNA editing","volume":"85","author":"Deng","year":"2025","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jmgm.2026.109502_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2024.168548","article-title":"DockThor-VS: a free platform for receptor-ligand virtual screening","volume":"436","author":"Guedes","year":"2024","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jmgm.2026.109502_bib17","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera\u2014A visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.jmgm.2026.109502_bib18","article-title":"AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","author":"Trott","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.jmgm.2026.109502_bib19","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.1113150","article-title":"Inositol hexakisphosphate is bound in the ADAR2 core and required for RNA editing","volume":"309","author":"Macbeth","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.jmgm.2026.109502_bib20","doi-asserted-by":"crossref","DOI":"10.1063\/5.0012280","article-title":"CHARMM-GUI supports the Amber force fields","volume":"153","author":"Lee","year":"2020","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.jmgm.2026.109502_bib21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1021\/acs.jctc.5b00935","article-title":"CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field","volume":"12","author":"Lee","year":"2016","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.jmgm.2026.109502_bib22","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/jcc.20945","article-title":"CHARMM\u2010GUI: a web\u2010based graphical user interface for CHARMM","volume":"29","author":"Jo","year":"2008","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.jmgm.2026.109502_bib23","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.jmgm.2026.109502_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1\u20132","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.jmgm.2026.109502_bib25","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.bpj.2015.08.015","article-title":"MDTraj: a modern open library for the analysis of molecular dynamics trajectories","volume":"109","author":"McGibbon","year":"2015","journal-title":"Biophys. J."},{"key":"10.1016\/j.jmgm.2026.109502_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaa161","article-title":"MolAICal: a soft tool for 3D drug design of protein targets by artificial intelligence and classical algorithm","volume":"22","author":"Bai","year":"2021","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.jmgm.2026.109502_bib27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jmgm.2011.06.003","article-title":"Insight into mechanism of small molecule inhibitors of the MDM2\u2013p53 interaction: molecular dynamics simulation and free energy analysis","volume":"30","author":"Chen","year":"2011","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.jmgm.2026.109502_bib28","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1021\/acs.jcim.2c00961","article-title":"Decoding the identification mechanism of an SAM-III riboswitch on ligands through multiple independent gaussian-accelerated molecular dynamics simulations","volume":"62","author":"Chen","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.jmgm.2026.109502_bib29","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40265-018-0895-5","article-title":"Sofosbuvir\/Velpatasvir\/Voxilaprevir: a review in chronic hepatitis C","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jmgm.2026.109502_bib30","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","author":"Wolin","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.jmgm.2026.109502_bib31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40265-013-0052-0","article-title":"Pasireotide: a review of its use in cushing's disease","volume":"73","author":"McKeage","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.jmgm.2026.109502_bib32","first-page":"25","article-title":"[Analysis of the efficacy and safety profile of sofosbuvir\/velpatasvir\/voxilaprevir in the treatment of patients with chronic hepatitis C with failed DAAs therapy]","volume":"32","author":"Guo","year":"2024","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"10.1016\/j.jmgm.2026.109502_bib33","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa171","article-title":"Pasireotide: a novel treatment for tumor-induced hypoglycemia due to insulinoma and non-islet cell tumor hypoglycemia","volume":"5","author":"Siddiqui","year":"2021","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.jmgm.2026.109502_bib34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11102-019-01021-2","article-title":"Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a phase 3 study","volume":"23","author":"Lacroix","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.jmgm.2026.109502_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-14-0360","article-title":"Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors","volume":"22","author":"Cives","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.jmgm.2026.109502_bib36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41586-018-0768-9","article-title":"Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade","volume":"565","author":"Ishizuka","year":"2019","journal-title":"Nature"}],"container-title":["Journal of Molecular Graphics and Modelling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326326002287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326326002287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:31:10Z","timestamp":1788535870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1093326326002287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":36,"alternative-id":["S1093326326002287"],"URL":"https:\/\/doi.org\/10.1016\/j.jmgm.2026.109502","relation":{},"ISSN":["1093-3263"],"issn-type":[{"value":"1093-3263","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond the catalytic site: Voxilaprevir and Pasireotide as repurposed therapeutics for conformational inhibition of ADAR1","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Graphics and Modelling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmgm.2026.109502","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109502"}}